As shown in Figure 1A, the results of Oncomine revealed that both MECOM and PRDM16 expression were downregulated in lung, breast, gastric, sarcoma, and kidney tumors compared with normal tissues (all p < 0.05). This evidence concerns the gene PRDM16 and sarcoma.